



RECEIVED  
DEC - 5 2001  
TECH CENTER 1600/2900

1655  
#19  
B. Webb  
12/14/01

A33131 PCT-USA (067858.0101)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vivier et al.  
Serial No. : 09/529,759 Examiner: Chakrabarti, A.  
Filed : April 18, 2000 Group Art Unit: 1655  
For : DOCUMENTING REPERTOIRES OF NKR  
IMMUNORECEPTORS AND/OR OF ACTIVATORY OR  
NON-INHIBITORY IMMUNORECEPTOR COUNTERPARTS  
OF NKR IMMUNORECEPTORS

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

October 19, 2001  
Date of Deposit

Carmella L. Stephens  
Attorney Name

41,328  
Registration No.

Carmella L. Stephens  
Signature

October 19, 2001  
Date of Signature

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants, by their attorneys, hereby brings the following documents to the attention of the Examiner in connection with the examination of the above-captioned patent application:

NY02:352118.1  
12/04/2001 SZEWDIE1 00000036 09529759

01 FC:126

180.00 OP

1. Yabe et al., "A multigene family on human chromosome 12 encodes natural killer-cell lectins", *Immunogenetics*, 37:455-460, 1993
2. Adamkiewicz et al., "Natural killer lectin-like receptors have divergent carboxy-termini, distinct from C-type lectins", *Immunogeneics*, 39:218, 1994;
3. Albi et al., "Natural Killer (NK)-Cell Function Antileukemic Activity of a Large Population of CD3<sup>+</sup>/CB8<sup>+</sup> T Cells Expressing NK Receptors for Major Histocompatibility Complex Class I After "Threese-Loci" HLA-Incompatible Bone Marrow Transplantation", *Blood*, 87:3993-4000, 1996;
4. Bottini et al., "A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation", *Eur. J. Imm.* 26:1816-1824, 1996;
5. Mingari et al., "Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor", 1997, *Eur. J. Immunol.*, 27:1374-1380, 1997;
6. Cambiaggi et al., "Natural killer cell acceptance of H-2 mismatch bone marrow grafts in transgenic mice expressing HLA-Cw3 specific killer cell inhibitory receptor (CD158b)", *Proc. Natl Acad. Sci.*, 94:8088-8092, 1997; and
7. Hiby et al., "Human Uterine NK Cells Have A Similar Repertoire of Killer Inhibitory and Activatory Receptors to Those Found in Blood, As Demonstrated By RT-PCR and Sequencing", *Molecular Immunology*, 34:419-430, 1997.

A PTO-1449 form and a copy of each of the above-listed documents is enclosed. The International Search Report was previously filed on April 18, 2000, citing the above-references.

A33131 PCT-USA (067858.0101)


PATENT

Identification of the above-listed references is not to be construed as an admission of the Applicants or the Attorneys of the Applicants that seek references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the above-mentioned application.

This Information Disclosure Statement is being filed after receipt of a first Office Action, therefore, we are enclosing a check in the amount of \$180.00. The Commissioner is hereby authorized to charge payment of any additional fees required under 37 C.F.R. 1.16, 1.17 and 1.21(h) associated with this communication or credit any overpayment to Deposit Account No. 02-4377.

Respectfully submitted,



John D. Murnane  
PTO Reg. No. 29,836  
Attorney for Applicants  
Carmella L. Stephens  
PTO Reg. No. 41,328  
Agent for Applicants  
(212) 408-2539